Alpha-fetoprotein-producing gastric cancer

Byaibio

Alpha-fetoprotein-producing gastric cancer (AFPGC) is a distinct gastric malignancy subtype with aggressive biology, elevated AFP, and clinicopathological and molecular features that differ from conventional gastric cancer. It is notable for biomarker-driven prognosis, where serum alpha fetoprotein correlates closely with tumor T-stage and outcome, and co-elevation of carcinoembryonic antigen can aid early diagnosis and prognostic evaluation, especially in advanced disease. Molecularly, AFPGC is associated with ccne1 amplification, erbb2 amplification, and recurrent muc16 and tp53 mutations, supporting its classification as a genomically distinctive entity. The disease also has emerging immunotherapy relevance, with preliminary efficacy reported for immune checkpoint inhibitors in some cases. Overall, AFPGC is recognized as a high-risk gastric cancer subtype in which AFP-based monitoring and molecular profiling may inform prognosis and treatment selection.

Biomarker and Prognosis

Molecular Features

  • ccne1 amplification is reported in AFPGC, consistent with its aggressive molecular profile. (PMID:41978393)
  • erbb2 amplification is also reported in AFPGC, highlighting a potentially targetable alteration. (PMID:41978393)
  • muc16 and tp53 mutations are part of the molecular signature often seen in AFPGC. (PMID:41978393)

Treatment and Immunotherapy

  • immune checkpoint inhibitors have shown preliminary efficacy in some AFPGC cases, suggesting immunotherapy may be relevant for selected patients. (PMID:41978393)
  • A 2026 Journal of Peking University Health Sciences review (PMID:41978393) emphasized the frontier issues in AFPGC, including immunotherapy considerations. (PMID:41978393)